Article
Myasthenia Gravis: An Update on Key Selected Pipeline Developments and Clinical Trials
IQVIA Pipeline Link and IQVIA Trial Link
Jul 16, 2024
Download
Myasthenia gravis is a rare neuromuscular disorder characterized by muscle weakness stemming from an autoimmune response, in which the body's immune system erroneously targets and gradually damages certain receptors within muscles that receive nerve signals. Patients with myasthenia gravis mainly exhibit autoantibodies against acetylcholine receptors (AChRs) which disrupt the transmission of signals between nerve endings and muscle fibers by inducing downregulation, destruction, functional blocking of AChRs, or interfering with the clustering of AChRs in the postsynaptic membrane.

Common symptoms associated with myasthenia gravis include weakness in the muscles of the eyes, resulting in eyelid drooping, double vision or blurred vision, as well as weakness in the muscles of the face, neck, arms, legs and throat. The condition most commonly affects young adult women aged below 40 years and older men aged 60 years and above. According to the Myasthenia Gravis Foundation of America, the prevalence of myasthenia gravis in the USA is estimated at 14 to 20 per 100,000 population.

Download the full article to learn more about the treatment options for Myasthenia Gravis, novel therapies in development, the clinical trial landscape, insights on early-stage agents for Myasthenia Gravis and more. 
Contact Us